entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 21:37:22 - browse：95554

The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Cell nuclei (blue), actin (red), and an actin regulator (green) are also shown. — Metastatic melanoma cells Julio C. Valencia,/NCI Center for Cancer Research

Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.

“It’s so exciting and gratifying,” said Allison Betof Warner, a cell therapy researcher and physician at Stanford University who has worked on Amtagvi. “This is a game-changing moment for our field. We’ve seen huge success of cellular therapy for hematologic malignancies, and we’ve yet to capitalize on that for solid tumors. This is hopefully the first of many to come.”

In a Phase 2 clinical trial, titled C-144-01, 153 patients who had already been on a median of three prior lines of therapy received lifileucel, and 31% of them responded to therapy. “These are in very late line patients. They’ve exhausted every standard care option,” Betof Warner said. “The most promising part of this therapy for me is that 42% of patients who responded were still responding for 18 months or longer. It’s truly incredible.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

focus

WSS

N.Y. state detects polio case, first in the U.S. since 2013

Arc Institute generative AI designs new CRISPR systems

With measles on the rise, a personal story of a devastating disease

Why 40% Americans with Parkinson’s don’t see a neurologist

Cytokinetics CEO stresses company can launch heart drug on its own

Iowa House, Senate pass 6

explore

entertainment

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

It's time to retire 'poor historian' from clinicians' vocabularies

Hepatitis C has a cure — but many Americans still lack access to it

Living with Fabry disease, a condition that causes chronic pain

The high cost of giving birth even with insurance

NVIDIA and Google execs on the future of AI and drug discovery

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Palantir health business leans on meeting customers’ needs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Solving academic medical centers' existential crisis

hotspot

Study: Pain burden is higher in Black NFL players than white ones

Addiction experts warn against a second 'war on drugs'

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Retired US general questions alleged Putin, Prigozhin meeting

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

hotspot

entertainment

focus

focus